MarketPulse — Real-Time Financial News & Market Analysis

uniQure faces securities class action lawsuit alleging misstatements about Pivotal Study design and FDA approval. Lead plaintiff deadline: April 13, 2026.

$QURE plunged 49% after FDA rejected AMT-130 Phase I/II data for accelerated approval. Securities lawsuit filed; lead plaintiff deadline April 13, 2026.

Enphase Energy faces class action lawsuit over failure to disclose inventory management limitations and tax credit risks. Lead plaintiff deadline: April 20, 2026.

Kyndryl ($KD) faces class action lawsuit after 55% stock decline following February disclosure of material weaknesses in internal controls and delayed 10-Q filing.

Rosen Law Firm urges Paysafe investors to join securities class action alleging disclosure failures, with April 7, 2026 lead plaintiff deadline.

Navan faces securities class action over failing to disclose $95M sales expense surge (39% increase) in Q3 2025. Investors with $100K+ losses have until April 24, 2026 to file.

Corcept Therapeutics faces securities class action after FDA rejected lead drug relacorilant. Stock plummeted 50.4%; lead plaintiff deadline set for April 21, 2026.

Ultragenyx Pharmaceutical faces securities lawsuit after setrusumab trial failure caused 42% stock decline. Lead plaintiff deadline April 6, 2026.

Rosen Law Firm files class action against $LAKE over alleged false statements regarding Pacific Helmets, Jolly divisions. Lead plaintiff deadline April 24, 2026.

Securities class action filed against $MREO for allegedly misleading investors about Phase 3 clinical trial results. Lead plaintiff deadline April 6, 2026.

CoreWeave ($CRWV) faces securities class action lawsuit alleging false demand statements and understated supplier risks. Lead plaintiff deadline: March 13, 2026.

Rosen Law Firm seeks lead plaintiffs in class action against NuScale Power ($SMR) alleging false statements about partner ENTRA1's nuclear experience. Deadline: April 20, 2026.

Class action lawsuit filed against $BRBR for allegedly concealing that sales growth stemmed from customer inventory accumulation rather than genuine demand, triggering 33% stock plunge.

Class action lawsuit filed against Vistagen Therapeutics after Phase 3 trial failure causes 80% stock plunge. Investors have until March 16, 2026 deadline.

Nvidia retains AI chip market dominance with 86% share and 65% growth despite AMD's $100B Meta deal and 34% revenue growth, supported by superior CUDA ecosystem and lower valuation multiple.

Rosen Law Firm urges Masonite investors who sold stock between June 2023 and February 2024 to join securities lawsuit alleging material disclosure failures.

Rosen Law Firm filed securities class action against Enphase Energy ($ENPH) alleging false statements on inventory management and tax credit impacts. Lead plaintiff deadline April 20, 2026.

Blue Hat Interactive delays 1-for-50 reverse stock split to March 9 from March 6, affecting 154.9M shares as part of equity restructuring.

Rosen Law Firm files securities class action against $NAVN, alleging false IPO disclosures about sales expenses. Lead plaintiff deadline set for April 24, 2026.

Accel Entertainment stock surged 18% after beating Q4 earnings estimates with record $341M revenue and near-doubled net income of $16.2M.